U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H44O4
Molecular Weight 420.6252
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OBETICHOLIC ACID

SMILES

[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O

InChI

InChIKey=ZXERDUOLZKYMJM-ZWECCWDJSA-N
InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1

HIDE SMILES / InChI
Molecular Formula C26H44O4
Molecular Weight 420.6252
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 11
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Obeticholic acid (also known as INT-747), is a potent, orally bioavailable farnesoid X receptor (FXR) agonist. The key role of the farnesoid X receptor (FXR) as a regulator of bile and cholesterol metabolism in the liver, with preclinical data from numerous studies providing strong rationale for the advancement of FXR agonists as hepatoprotective therapeutics in chronic liver disease. Obeticholic acid is marketed under the trade name Ocaliva. Ocaliva is specifically indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

Originator

Approval Year

2016
495
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 0.09 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
OCALIVA

Approved Use

OCALIVA, a farnesoid X receptor (FXR) agonist, is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

Launch Date

1.46430715E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
68.3 ng/mL
OTHER GOV
https://www.ema.europa.eu/en/documents/assessment-report/ocaliva-epar-public-assessment-report_en.pdf
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OBETICHOLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
747 ng × h/mL
OTHER GOV
https://www.ema.europa.eu/en/documents/assessment-report/ocaliva-epar-public-assessment-report_en.pdf
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OBETICHOLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf
OBETICHOLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
unhealthy, 56 years (range: 29 - 86 years)
n = 73
Health Status: unhealthy
Condition: primary biliary cholangitis
Age Group: 56 years (range: 29 - 86 years)
Sex: M+F
Population Size: 73
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
Disc. AE: Pruritus...
AEs leading to
discontinuation/dose reduction:
Pruritus (10%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
50 mg 1 times / day multiple, oral
Overdose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
unhealthy
Health Status: unhealthy
Condition: primary biliary cholangitis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
Other AEs: Ascites, Jaundice...
Other AEs:
Ascites
Jaundice
Portal hypertension
Primary biliary cholangitis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Pruritus 10%
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
unhealthy, 56 years (range: 29 - 86 years)
n = 73
Health Status: unhealthy
Condition: primary biliary cholangitis
Age Group: 56 years (range: 29 - 86 years)
Sex: M+F
Population Size: 73
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
Ascites
50 mg 1 times / day multiple, oral
Overdose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
unhealthy
Health Status: unhealthy
Condition: primary biliary cholangitis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
Jaundice
50 mg 1 times / day multiple, oral
Overdose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
unhealthy
Health Status: unhealthy
Condition: primary biliary cholangitis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
Portal hypertension
50 mg 1 times / day multiple, oral
Overdose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
unhealthy
Health Status: unhealthy
Condition: primary biliary cholangitis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
Primary biliary cholangitis
50 mg 1 times / day multiple, oral
Overdose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
unhealthy
Health Status: unhealthy
Condition: primary biliary cholangitis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587

inducer
781
inducer
389

inhibitor
1767
inhibitor
1852

inducer
97
inducer
23

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2B6
810

CYP2C8
911

CYP2C19
1478
BCRP
561

MRP2
205

MRP3
50

MRP4
77

BSEP
52

P-gp
1537

ASBT
3

NTCP
17

MATE1
135

MATE2
96

OATP1B1
406

OATP1B3
350

OAT1
326

OAT3
339

OCT1
327

OCT2
355
CYP1A2
701

CYP2B6
547

CYP2C8
168

CYP2C19
293

P-gp
257

BCRP
75

OATP1B1
26

OATP1B3
6

OCT2
6

BSEP
6

MRP2
111

MRP3
53

MRP4
32

ASBT
1

OCT1
35
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1925
 no [IC50 44 uM]
Tauro-OCA
1
CYP2C8
965
 no [IC50 9.2 uM]
Glyco-OCA
1
P-gp
1650
 no [IC50 >100 uM]
P-gp
1650
 no [IC50 >100 uM]
Glyco-OCA
1
P-gp
1650
 no [IC50 >100 uM]
Tauro-OCA
1
OCT2
648
 no [IC50 >30 uM]
OCT2
648
 no [IC50 >30 uM]
Glyco-OCA
1
OCT2
648
 no [IC50 >30 uM]
Tauro-OCA
1
BCRP
773
 no [IC50 >300 uM]
Glyco-OCA
1
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of RSV increased by 30% and 26%, respectively
Page: 83.0
CYP1A2
1692
 no [IC50 >50 uM]
CYP2B6
1001
 no [IC50 >50 uM]
Glyco-OCA
1
CYP2C19
1553
 no [IC50 >50 uM]
CYP2C8
965
 no [IC50 >50 uM]
Tauro-OCA
1
CYP2C9
1819
 no [IC50 >50 uM]
Glyco-OCA
1
CYP2D6
1891
 no [IC50 >50 uM]
CYP2D6
1891
 no [IC50 >50 uM]
Tauro-OCA
1
CYP1A2
1692
 no
CYP1A2
1692
 no
Glyco-OCA
1
CYP1A2
1692
 no
Tauro-OCA
1
CYP1A2
1692
 no
Tauro-OCA
1
CYP2B6
1001
 no
CYP2B6
1001
 no
Glyco-OCA
1
CYP2B6
1001
 no
Tauro-OCA
1
CYP2C19
1553
 no
CYP2C19
1553
 no
Glyco-OCA
1
CYP2C19
1553
 no
Tauro-OCA
1
CYP2C8
965
 no
CYP2C8
965
 no
Glyco-OCA
1
CYP2C8
965
 no
Tauro-OCA
1
CYP2C9
1819
 no
CYP2C9
1819
 no
Glyco-OCA
1
CYP2C9
1819
 no
Tauro-OCA
1
CYP2D6
1891
 no
CYP2D6
1891
 no
Glyco-OCA
1
CYP2D6
1891
 no
Tauro-OCA
1
CYP3A4
1925
 no
CYP3A4
1925
 no
Glyco-OCA
1
CYP3A4
1925
 no
Tauro-OCA
1
CYP3A4
1925
 no
Glyco-OCA
1
CYP2C19
1553
 no
Glyco-OCA
1
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of omeprazole increased by 36% and 15%, respectively (Table 37). AUCinf and Cmax of 5-hydroxy-omeprazole increased by about 18% and 3.4%, respectively
Page: 74.0
CYP2C8
965
 unlikely [IC50 40 uM]
CYP2C19
1553
 unlikely [IC50 50 uM]
Tauro-OCA
1
BSEP
403
 yes [IC50 10.5 uM]
Tauro-OCA
1
CYP2C9
1819
 yes [IC50 11 uM]
Tauro-OCA
1
no (co-administration study)
Comment: Although the systemic exposure of S-warfarin was increased following multiple doses of OCA 10 or 25 mg QD, the INR changes were <10% except the Emax change, which was only 1.1% more than 10%, following 10 mg dose
Page: 74.0
CYP2C9
1819
 yes [IC50 12 uM]
MRP2
475
 yes [IC50 126 uM]
Glyco-OCA
1
CYP2B6
1001
 yes [IC50 13 uM]
Tauro-OCA
1
CYP1A2
1692
 yes [IC50 13 uM]
Glyco-OCA
1
yes (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of caffeine increased by 65% and 10%, respectively
Page: 74.0
BSEP
403
 yes [IC50 13.7 uM]
MRP4
238
 yes [IC50 131 uM]
Tauro-OCA
1
OCT1
543
 yes [IC50 138 uM]
Tauro-OCA
1
MRP3
207
 yes [IC50 14.6 uM]
Glyco-OCA
1
BCRP
773
 yes [IC50 146 uM]
Tauro-OCA
1
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of RSV increased by 30% and 26%, respectively
Page: 83.0
CYP2B6
1001
 yes [IC50 15 uM]
CYP3A4
1925
 yes [IC50 19 uM]
no (co-administration study)
Comment: following multiple doses of OCA 25 mg QD, AUCinf and Cmax of midazolam increased by 26% and 17%, respectively
Page: 74.0
OATP1B3
715
 yes [IC50 2.15 uM]
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of RSV increased by 30% and 26%, respectively
Page: 83.0
OATP1B1
803
 yes [IC50 2.57 uM]
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of RSV increased by 30% and 26%, respectively
Page: 83.0
OATP1B3
715
 yes [IC50 2.93 uM]
Glyco-OCA
1
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of RSV increased by 30% and 26%, respectively
Page: 83.0
OATP1B3
715
 yes [IC50 2.95 uM]
Tauro-OCA
1
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of RSV increased by 30% and 26%, respectively
Page: 83.0
MRP2
475
 yes [IC50 205 uM]
Tauro-OCA
1
BCRP
773
 yes [IC50 21.1 uM]
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of RSV increased by 30% and 26%, respectively
Page: 83.0
ASBT
6
 yes [IC50 21.5 uM]
Tauro-OCA
1
ASBT
6
 yes [IC50 27.2 uM]
Glyco-OCA
1
OATP1B1
803
 yes [IC50 3.01 uM]
Tauro-OCA
1
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of RSV increased by 30% and 26%, respectively
Page: 83.0
OCT1
543
 yes [IC50 30 uM]
CYP2D6
1891
 yes [IC50 35 uM]
Glyco-OCA
1
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of DXM decreased by 11% and 17.4%, respectively
Page: 74.0
OATP1B1
803
 yes [IC50 4.05 uM]
Glyco-OCA
1
no (co-administration study)
Comment: Following multiple doses of OCA 25 mg QD, AUCinf and Cmax of RSV increased by 30% and 26%, respectively
Page: 83.0
ASBT
6
 yes [IC50 43.1 uM]
MRP4
238
 yes [IC50 45.6 uM]
MRP3
207
 yes [IC50 5.64 uM]
MRP3
207
 yes [IC50 51 uM]
Tauro-OCA
1
BSEP
403
 yes [IC50 6.9 uM]
Glyco-OCA
1
MRP4
238
 yes [IC50 68.5 uM]
Glyco-OCA
1
MRP2
475
 yes [IC50 69.4 uM]
OCT1
543
 yes [IC50 93.3 uM]
Glyco-OCA
1
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
ASBT
3
 no
BCRP
561
 no
BCRP
561
 no
Glyco-OCA
1
BCRP
561
 no
Tauro-OCA
1
BSEP
52
 no
MATE1
135
 no
MATE1
135
 no
Glyco-OCA
1
MATE1
135
 no
Tauro-OCA
1
MATE2
96
 no
MATE2
96
 no
Glyco-OCA
1
MATE2
96
 no
Tauro-OCA
1
MRP2
205
 no
MRP2
205
 no
Glyco-OCA
1
MRP2
205
 no
Tauro-OCA
1
MRP3
50
 no
MRP3
50
 no
Glyco-OCA
1
MRP3
50
 no
Tauro-OCA
1
MRP4
77
 no
MRP4
77
 no
Glyco-OCA
1
MRP4
77
 no
Tauro-OCA
1
NTCP
17
 no
OAT1
326
 no
OAT1
326
 no
Glyco-OCA
1
OAT1
326
 no
Tauro-OCA
1
OAT3
339
 no
OATP1B1
406
 no
OATP1B3
350
 no
OCT1
327
 no
OCT1
327
 no
Glyco-OCA
1
OCT1
327
 no
Tauro-OCA
1
OCT2
355
 no
OCT2
355
 no
Glyco-OCA
1
OCT2
355
 no
Tauro-OCA
1
P-gp
1537
 weak
ASBT
3
 yes
Glyco-OCA
1
ASBT
3
 yes
Tauro-OCA
1
BSEP
52
 yes
Glyco-OCA
1
NTCP
17
 yes
Glyco-OCA
1
NTCP
17
 yes
Tauro-OCA
1
OAT3
339
 yes
Glyco-OCA
1
OAT3
339
 yes
Tauro-OCA
1
OATP1B1
406
 yes
Glyco-OCA
1
OATP1B1
406
 yes
Tauro-OCA
1
OATP1B3
350
 yes
Glyco-OCA
1
OATP1B3
350
 yes
Tauro-OCA
1
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:43602
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:43602
MolPort
MolPort-035-682-579
https://www.molport.com/shop/molecule-link/MolPort-035-682-579
ZINC
ZINC000014164617
http://zinc15.docking.org/substances/ZINC000014164617
PubMed

PubMed

TitleDatePubMed
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.
2005 May
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
2005 Oct
Patents

Patents

US20160074419
1

Sample Use Guides

In Vivo Use Guide
Starting Dosage: The recommended starting dosage of OCALIVA is 5 mg orally once daily in adults who have not achieved an adequate response to an appropriate dosage of UDCA for at least 1 year or are intolerant to UDCA.
Route of Administration: Oral
In Vitro Use Guide
In HuH7 cells, Obeticholic Acid acts as a potent FXR agonist with EC50 of 85 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:18:31 UTC 2023
Edited
by admin
on Fri Dec 15 17:18:31 UTC 2023
Record UNII
0462Z4S4OZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OBETICHOLIC ACID
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
Obeticholic acid [WHO-DD]
Common Name English
(3.ALPHA.,5.BETA.,6.ALPHA.,7.ALPHA.)-6-ETHYL-3,7-DIHYDROXYCHOLAN-24-OIC ACID
Common Name English
obeticholic acid [INN]
Common Name English
DSP-1747
Code English
OCALIVA
Common Name English
INT-747
Code English
6-ETHYLCHENODEOXYCHOLIC ACID
Common Name English
OBETICHOLIC ACID [JAN]
Common Name English
OBETICHOLIC ACID [MI]
Common Name English
6-ECDCA
Common Name English
CHOLAN-24-OIC ACID, 6-ETHYL-3,7-DIHYDROXY-, (3.ALPHA.,5.BETA.,6.ALPHA.,7.ALPHA.)-
Common Name English
OBETICHOLIC ACID [USAN]
Common Name English
OBETICHOLIC ACID [ORANGE BOOK]
Common Name English
6-ALPHA-ETHYLCHENODEOXYCHOLIC ACID
Common Name English
Classification Tree Code System Code
NDF-RT N0000192561
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
NCI_THESAURUS C1636
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
EU-Orphan Drug EU/3/10/753
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
FDA ORPHAN DRUG 253207
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
FDA ORPHAN DRUG 259008
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
WHO-ATC A05AA04
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
FDA ORPHAN DRUG 937523
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
Code System Code Type Description
CHEBI
43602
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
EPA CompTox
DTXSID20196671
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
DRUG CENTRAL
5155
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
RXCUI
1798288
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
MERCK INDEX
m11955
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
DRUG BANK
DB05990
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
FDA UNII
0462Z4S4OZ
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
NCI_THESAURUS
C80837
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
CAS
459789-99-2
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
WIKIPEDIA
Obeticholic acid
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
INN
9084
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
EVMPD
SUB91981
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
ChEMBL
CHEMBL566315
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
NDF-RT
N0000192560
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY Farnesoid X Receptor Agonists [MoA]
SMS_ID
100000141528
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
USAN
TT-137
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
DAILYMED
0462Z4S4OZ
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
PUBCHEM
447715
Created by admin on Fri Dec 15 17:18:31 UTC 2023 , Edited by admin on Fri Dec 15 17:18:31 UTC 2023
PRIMARY
Related Record Type Details
Structure of OBETICHOLIC ACID
CUMULATIVE EXCRETION
CYTOCHROME P450 1A2
METABOLIC ENZYME->INHIBITOR OF EXPRESSION
The effect of 10 mg OCA on CYP1A2 substrate caffeine showed that systemicexposure to caffeine increased by 42%. The systemic exposure to caffeine increased by 65% following 25 mg OCA.
RETINOID X RECEPTOR ALPHA
TARGET -> INHIBITOR
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA
TARGET -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
BILE ACID RECEPTOR
TARGET -> AGONIST
Structure of OBETICHOLIC ACID
CUMULATIVE EXCRETION
Following an oral administration of 25 mg [14C]-OCA, about 87% of the dose is excreted in feces through biliary secretion. Less than 3% of the dose is excreted in the urine with no detection of OCA.
FECAL
Related Record Type Details
Structure of TAURO-OBETICHOLIC ACID
METABOLITE ACTIVE -> PARENT
Structure of GLYCO-OBETICHOLIC ACID
METABOLITE ACTIVE -> PARENT
AMOUNT ADMINISTERED
PLASMA
Structure of OBETICHOLIC ACID 3-GLUCURONIDE
METABOLITE -> PARENT
Structure of OBETICHOLIC ACID 24-GLUCURONIDE
METABOLITE -> PARENT
Related Record Type Details
Structure of 7-EPI-OBETICHOLIC ACID 3-OBETICHOLATE ESTER
IMPURITY -> PARENT
Related Record Type Details
Structure of OBETICHOLIC ACID
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC MULTIPLE ORAL ADMINISTRATION

ONCE DAILY DOSE

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966